Currently, it is recommended that all NSCLC patients with an adenocarcinoma component are tested for ALK rearrangements in their diagnostic biopsy, and several ALK TKIs are approved for the treatment of ALK-positive patients [1,2]. The gene discussed is ALK; the disease is adenocarcinoma.